Primary cytoreductive surgery and adjuvant hormone therapy in women with advanced low-grade serous carcinoma: Reducing overtreatment without compromising survival?

Trial ID #	Retrospective Study: Adjuvant Hormone Therapy in LGSC
Phase	Two sites
Drug Class	Hormonal Therapy: Aromatase
Drug Name	Letrozole
Alternate Drug Names	Femara
Drugs in Trial	Letrozole, Tamoxifen, Anastrozole
Eligible Participant	Stage II-IV low grade serous ovarian cancer
Patients Enrolled	27; 85% optimally debulked, 96% HR+, 32% PR+
Therapy Setting	First-line
Study Design	Open-Label, Non-randomized
Endpoints	PFS, OS, evaluated per RECIST
Efficacy	Surgery+adjuvant hormone therapy: PFS: Not Reached (41 months follow up) OS: Not Reached (41 months follow up) 2 year PFS and OS: 82.8% and 96.3% 3 year PFS and OS: 79.0% and 92.6%
Conclusion	Promising PFS and OS in Low Grade Serous Cancer patients treated with hormone therapy following cytoreductive surgery
Reference	Fader AN et al. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? Gynecol Oncol (2017) 147: 85-91 https://www.ncbi.nlm.nih.gov/pubmed/28768570